Connect Biopharma
Updated: April 20, 2026
Zheng Wei, Co-founder, CEO
Country: China | Funding: $215.2M (+)
Founded: 2012
Website: https://www.connectbiopharma.com/
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation like asthma and COPD. The Company’s lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha and has demonstrated activity in both atopic dermatitis and asthma. It has a distinct epitope that is different from dupilumab and has achieved equivalent effects with lower concentration than dupilumab. The company is also building a deep and compelling pipeline of product candidates with the potential to advance care and outcomes for patients with diverse autoimmune or inflammatory diseases.
Founded: 2012
Website: https://www.connectbiopharma.com/
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation like asthma and COPD. The Company’s lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha and has demonstrated activity in both atopic dermatitis and asthma. It has a distinct epitope that is different from dupilumab and has achieved equivalent effects with lower concentration than dupilumab. The company is also building a deep and compelling pipeline of product candidates with the potential to advance care and outcomes for patients with diverse autoimmune or inflammatory diseases.
